Cryptocurrency & Digital Assets

New data reveals Orasis Pharma's Qlosi eye drops offer a 'pupil selective' approach to presbyopia, promising fewer side effects than rival treatments.

Affluent travelers are spending more but seeking meaning over opulence. A new report shows how wellness, advisors, and payments are shaping travel's future.

Omeros begins sales of YARTEMLEA, the first and only approved therapy for TA-TMA, a fatal complication of stem cell transplants, shifting the paradigm.

Pritzker Alternative Strategies hires Joseph Kusnan, signaling a strategic move to leverage deep family office expertise in competitive private equity markets.

Webull's new $0 commission sports prediction markets mix investing and entertainment, but critics question if it's a financial tool or a new way to gamble.

A new report reveals churches using digital tools saw a surge in engagement, giving, and Gen Z attendance in 2025, with non-cash gifts like crypto booming.

A historic firehouse is reborn as a luxury hotel with a mission, partnering with USC to create careers for individuals with disabilities. This changes everything.

Wisp's first acquisition marks a major strategy shift from D2C to enterprise care, aiming to close critical gaps in women's sexual health and PrEP access.

A new partnership will validate Obagi's first FDA-approved filler using real-world data across a national network, signaling a shift in the industry.

Bolt makes Affirm its default BNPL provider, a major move to streamline payments for merchants and challenge e-commerce giants in a booming market.

Semtech launches new ultra-low-power 5G RedCap routers, solving the dilemma between aging 4G and expensive 5G for critical off-grid infrastructure.

A new partnership aims to integrate advanced battery tech and custom controls, accelerating the shift to zero-emission machinery in demanding sectors.

A major price drop on high-quality synthetic DNA from Elegen is set to democratize research, accelerate innovation, and disrupt the biotech market.

Pulitzer-winning Russian democracy advocate Vladimir Kara-Murza brings his story of survival to Jacksonville to support Wolfson Children's Hospital.

China approves Libevitug, a first-in-class drug for the most severe form of hepatitis, marking a major milestone for patients and global biotech innovation.

A Dubai-based PR firm leverages Web Summit Qatar to challenge industry giants, blending SEO with traditional newswire for the AI and Web3 era.

Activist investor Farallon Capital pressures insurer T&D Holdings with a public blueprint for reform, demanding bold changes ahead of its 2026 vision.

After its $172.5M IPO, Lawrence Ho-backed Black Spade III signals readiness to hunt for a tech-infused leisure company. What does this mean for investors?

A French biotech is advancing a novel class of drugs that don't just fight cravings but may reverse the deep-seated brain changes caused by addiction.

Over 19,000 people logged 280,000 screen-free hours in a single day, answering a call to address digital overload and youth mental health.